Evidence map›Paper›PMID 30311149›Full record

ArticleCardiovascular engineering and technology2019

Cardiac Valve Bioreactor for Physiological Conditioning and Hydrodynamic Performance Assessment.

Brandon J Tefft, Joshua A Choe, Melissa D Young, Ryan S Hennessy, David W Morse, Jeffery A Bouchard, Herbert J Hedberg, Joseph F Consiglio, Dan Dragomir-Daescu, Robert D Simari and 1 more

Abstract read
In one paragraph

Article in Cardiovascular engineering and technology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. A design-based model of the aortic valve for fluid-structure interaction.Biomechanics and modeling in mechanobiology · 2021
    Article
  4. Evaluation of the role of peripheral artery plaque geometry and composition on stent performance.Journal of the mechanical behavior of biomedical materials · 2021
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Brandon J TefftDepartment of Cardiovascular Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Joshua A ChoeDepartment of Cardiovascular Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Melissa D YoungDepartment of Cardiovascular Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Ryan S HennessyDepartment of Cardiovascular Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
David W MorseDepartment of Cardiovascular Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Jeffery A BouchardHarvard Apparatus, Holliston, MA, USA.
Herbert J HedbergHarvard Apparatus, Holliston, MA, USA.
Joseph F ConsiglioHarvard Apparatus, Holliston, MA, USA.
Dan Dragomir-DaescuDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.
Robert D SimariSchool of Medicine, University of Kansas, Kansas City, MO, USA.
Amir LermanDepartment of Cardiovascular Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. lerman.amir@mayo.edu.ORCID 0000-0002-9446-5313
Mayo Clinic · USMayo Clinic in Florida · USUniversity of Kansas · US

Funding

CARDIOVASOLOGYT32HL007111 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug · 1985 to 2026
$8.7M
Nanotechnology for magnetic endothelialization of implantable cardiovascular devicesK99HL129068 · NHLBI · MAYO CLINIC ROCHESTER · PI TEFFT, BRANDON J · 2016 to 2017
$267k
NHLBI NIH HHS K99 HL129068NHLBI NIH HHS T32 HL007111
6 · The paper itself

Abstract

purposeTissue engineered heart valves (TEHV) are being investigated to address the limitations of currently available valve prostheses. In order to advance a wide variety of TEHV approaches, the goal of this study was to develop a cardiac valve bioreactor system capable of conditioning living valves with a range of hydrodynamic conditions as well as capable of assessing hydrodynamic performance to ISO 5840 standards.

methodsA bioreactor system was designed based on the Windkessel approach. Novel features including a purpose-built valve chamber and pressure feedback control were incorporated to maintain asepsis while achieving a range of hydrodynamic conditions. The system was validated by testing hydrodynamic conditions with a bioprosthesis and by operating with cell culture medium for 4 weeks and living cells for 2 weeks.

resultsThe bioreactor system was able to produce a range of pressure and flow conditions from static to resting adult left ventricular outflow tract to pathological including hypertension. The system operated aseptically for 4 weeks and cell viability was maintained for 2 weeks. The system was also able to record the pressure and flow data needed to calculate effective orifice area and regurgitant fraction.

conclusionsWe have developed a single bioreactor system that allows for step-wise conditioning protocols to be developed for each unique TEHV design as well as allows for hydrodynamic performance assessment.

Indexed as

BioprosthesisBioreactorsHeart Valve ProsthesisAnimalsCell Culture TechniquesCell SurvivalEquipment DesignHeart ValvesHumansHydrodynamicsMiceNIH 3T3 CellsProsthesis DesignTime FactorsTissue EngineeringBiochemical stimulationBiomechanical stimulationISO 5840Three-dimensional tissue cultureTissue engineered heart valve

Identifiers

PMID30311149
PMCPMC6541400
OpenAlexW2895992098

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.